SYBILLA
Systems Biology of T-cell Activation in Health and Disease
| Coordinatore | ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Organization address
address: FAHNENBERGPLATZ contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.sybilla-t-cell.de/ |
| Totale costo | 14˙636˙311 € |
| EC contributo | 11˙100˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-04-01 - 2013-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Organization address
address: FAHNENBERGPLATZ contact info |
DE (FREIBURG) | coordinator | 0.00 |
| 2 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
| 3 |
ACIES SAS
Organization address
address: RUE DE LA REPUBLIQUE 69 contact info |
FR (LYON) | participant | 0.00 |
| 4 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 0.00 |
| 5 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 0.00 |
| 6 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 0.00 |
| 7 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 0.00 |
| 8 |
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH
Organization address
address: Raemistrasse 101 contact info |
CH (ZUERICH) | participant | 0.00 |
| 9 |
EXBIO PRAHA AS
Organization address
address: Nad Safinou II 341 contact info |
CZ (VESTEC) | participant | 0.00 |
| 10 |
FONDAZIONE HUMANITAS PER LA RICERCA
Organization address
address: Via Manzoni 56 contact info |
IT (ROZZANO) | participant | 0.00 |
| 11 |
Immune Disease Institute
Organization address
address: HUNTINGTON AVENUE 800 contact info |
US (BOSTON) | participant | 0.00 |
| 12 |
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
Organization address
address: PADRICIANO 99 contact info |
IT (TRIESTE) | participant | 0.00 |
| 13 |
Joslin Diabetes Center
Organization address
address: One Joslin place contact info |
US ("BOSTON, MASSACHUSETTS") | participant | 0.00 |
| 14 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 15 |
MEDICEL OY
Organization address
address: HAARTMANINKATU 8 contact info |
FI (HELSINKI) | participant | 0.00 |
| 16 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 0.00 |
| 17 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
| 18 |
OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG
Organization address
address: UNIVERSITAETSPLATZ 2 contact info |
DE (MAGDEBURG) | participant | 0.00 |
| 19 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 20 |
TTY-SAATIO
Organization address
address: Korkeakoulunkatu 10 contact info |
FI (TAMPERE) | participant | 0.00 |
| 21 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 0.00 |
| 22 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'T-cell activation, whether induced by pathogens or auto-antigens, is a complex process relying on multiple layers of tightly controlled intracellular signalling modules that form an intricate network. Defects in this network can cause severe and chronic disorders such as autoimmune diseases. Although 5% of the population suffer from these diseases, only a few therapeutic treatments are available. To a large extent this is attributed to the lack of systems-level insights, which would provide concepts of how to modulate T-cell activation. The SYBILLA project groups 14 partners from 9 different EU countries, including 3 SMEs. Through a multidisciplinary effort it aims to understand at the systems’ level, how T-cells discriminate foreign from auto-antigens. Towards this goal, a transgenic mouse system will be used as a tractable physiological model. Data will be validated in human T-cells and a humanised mouse model for multiple sclerosis. SYBILLA will develop technological and mathematical tools to generate and integrate high-density quantitative data describing T-cell activation. Proteomics, transcriptomics, metabolomics, imaging and multiplexed biochemical techniques will be applied to obtain holistic maps of T-cell signalling networks and to achieve a quantitative understanding of the network and its regulation in response to different inputs. Building upon our existing network model, constant iterations will be used to develop more robust dynamic models to describe the network’s response to perturbations. This will culminate in the generation of a Virtual T-Cell, allowing computer simulation to refine the predictability of physiological and pathophysiological reactions. SYBILLA’s impact on EU biopharmaceutical competitiveness will be enormous through identification of new pharmacologic targets, optimised prediction of immunomodulatory drug efficacy, discovery of new concerted biomarkers and improvement of personalised medication for treating autoimmune diseases.'
Introduzione (Teaser)
Autoimmune disorders impose a heavy socioeconomic burden on industrialised societies. Outlining the mechanisms responsible for such abnormal immune responses may give rise to new drugs and improve clinical outcome.
Altri progetti dello stesso programma (FP7-HEALTH)
EVERREST (2013)
Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction?
Read MoreBIO-NMD (2009)
Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders
Read MoreMOTIF (2012)
Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery
Read More